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Tracheo-Esophageal
Fistula with
Bevacizumab after
Mediastinal Radiation
To the Editor:
We report here a case of a young
man who developed a trachea-esophageal
fistula 4 months following thoracic radia-
tion while being treated with bevacizumab
and chemotherapy. A 28-year-old gentle-
man was diagnosed with non-small cell
lung cancer (NSCLC) when he presented
with a large right sided mediastinal mass.
Transbronchial biopsy results were con-
sistent with adenocarcinoma. Staging eval-
uation with computerized tomography,
flourodeoxyglucose positron emission to-
mography, and mediastinoscopy con-
firmed stage IIIB (T2N2M0) disease. He
was treated with definitive radiation (74
gray) and concurrent cisplatin with etopo-
side. One month after completing radio-
therapy, he developed progressive disease
with enlargement of cervical lymph
nodes. Biopsy of a cervical lymph node
was consistent with adenocarcinoma. Two
months after radiotherapy had been com-
pleted, he began systemic treatment with
carboplatin, paclitaxel, and bevacizumab
(15 mg/kg) every 3 weeks. After two cy-
cles, he had a partial response.
One week prior to his third cycle,
he developed progressive odynophagia,
then severe coughing with swallowing.
An endobronchial evaluation was per-
formed with visualization of a fistulous
communication between the esophagus
and the trachea, extending into the right
mainstem bronchus. An endotracheal
stent was placed, but after 2 weeks he
had no relief of his respiratory symp-
toms and was referred to our institution.
Bronchoscopy revealed a persistent tra-
cheoesophageal fistula which was not
excluded by the endotracheal stent. This
endotraheal stent was removed and the
fistula was visualized as seen in Figure 1A.
At that time, a covered esophageal stent
(18-mm diameter, 120-mm length, Alve-
olus) was placed in the esophagus to ex-
clude gastric and oral secretions from the
airway (Figure 1B). Biopsies of the fistu-
lous tract showed no evidence of malig-
nancy. As the computed tomography scan
of the chest and abdomen revealed pro-
gressive disease in the mediastinum and
liver, an attempt at surgical correction
was not considered appropriate. A jejunal
feeding tube was placed for nutrition,
and he was discharged homewith support-
ive care.
Bevacizumab, a monoclonal anti-
body targeting vascular endothelial
growth factor (VEGF), has been ap-
proved for the treatment of advanced
NSCLC in combination with paclitaxel
and carboplatin.1,2 Bevacizumab has
been associated with bleeding complica-
tions, hypertension and gastrointestinal
tract perforation.2 When administered in
combination with thoracic radiation, be-
vacizumab has recently been associated
with tracheo-esophageal fistulas. The
manufacturer issued a warning based on
the development of tracheo-esophageal
fistulas in 3 of 29 patients with limited
stage small cell lung cancer being
treated with definitive radiation, concur-
rent with irinotecan, carboplatin, and be-
vacizumab. Data from the manufacturer
(as of March 2007) refer to six other
instances in which patients with lung
and esophageal malignancies developed
tracheo-esophageal fistulas while being
treated with bevacizumab.3 A black box
warning regarding this complication
was mandated by the Food and Drug
Administration in April 2007;2 however,
no such reports are available at this time
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FIGURE 1. A, Tracheo-esophageal fistula in patient treated with bevacizumab. B,
Coated stent in the esophagus, as visualized through the large posterior airway defect.
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in the peer-reviewed medical literature.
Bevacizumab has been associated with
fistula formation in patients with colo-
rectal cancer and, more recently, in pa-
tients with head and neck cancer treated
concurrently with radiation.4 The mech-
anism of fistula formation with bevaci-
zumab is poorly understood, but it is
most likely that impaired angiogenesis
leads to delayed and dysfunctional wound
healing.5 Radiation and chronic inflamma-
tion are also known to predispose to fistula
formation. In the phase III trial which led
to the approval of bevacizumab for
NSCLC, prior thoracic radiotherapy was
allowed, and 33 such patients were in-
cluded in the trial, with no reports of
fistula formation. However, radiation dose
and timing were not presented.1
Tracheo-esophageal fistula is a rare
but life-threatening complication of anti-
angiogenic therapy with bevacizumab in
patients with thoracic malignancies, usu-
ally with concurrent mediastinal radiation.
As this unfortunate case illustrates, pa-
tients may be at risk for fistula develop-
ment even months after completing radia-
tion treatment. This complication may be
common to all inhibitors of the VEGF
pathway. For example, sunitinib has been
associated with rectal fistula formation in
the setting of previous radiation therapy.6
It is noteworthy that at least three studies
with concurrent thoracic radiation and be-
vacizumab are still open and currently
enrolling patients with locally advanced
NSCLC.7
The safety of bevacizumab in pa-
tients previously treated with mediastinal
radiation needs to be studied very care-
fully. We would advise against using bev-
caziumab concurrently or after mediasti-
nal radiation outside the context of a
carefully designed clinical trial. As this
is likely to be a class effect related to inhi-
bition of the VEGF pathway, caution should
be exercised in using any VEGF inhibitors
in combination with thoracic radiation.
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